{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:31:56Z","timestamp":1774935116198,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"Korea National Research Foundation","doi-asserted-by":"crossref","award":["NRF-2021R1C1C1004569"],"award-info":[{"award-number":["NRF-2021R1C1C1004569"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>A risk-stratification strategy can improve the effectiveness of intensive hepatocellular carcinoma (HCC) surveillance with an alternative modality. However, such strategies and prediction models incorporating ultrasound features remain undeveloped for a suitable population. Therefore, we developed and validated an HCC risk prediction model using ultrasound features in patients with viral hepatitis who are potentially eligible for intensive surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      This retrospective multicenter study included 17,557 HCC-na\u00efve patients with viral hepatitis who underwent US surveillance between 2005 and 2015. In the development dataset (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097918), clinical and US features were analyzed to establish the prediction model. Factors associated with HCC were identified by multivariable Cox regression analysis. Model performance was compared to existing prediction models in internal (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093393) and external (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096246) validation datasets.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The SELECT model included age, male sex, diabetes, serum albumin and alanine aminotransferase levels, platelet count, and ultrasound-detected cirrhosis and multiple cirrhotic nodules. In the external validation dataset, the low-, intermediate-, and high-risk groups had 0.8%, 6.9%, and 16.1% 5-year cumulative HCC incidence, respectively. In those with an estimated annual HCC incidence \u2265 2.5% (SELECT score &gt; \u22122.04), the 5-year cumulative HCC incidence was 15.5%. The SELECT model had better discrimination capability than aMAP, THRI, ADRESS-HCC, the Velazquez score, and mPAGE-B (Uno C-index, 0.791 vs. 0.740, 0.668, 0.658, 0.650, and 0.740, respectively; all adjusted\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The SELECT model better estimated HCC risk than other models in viral hepatitis patients. Intensive surveillance with alternative modalities may be considered based on this model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Ultrasound features have not been incorporated into hepatocellular carcinoma risk prediction models, despite ultrasound being the primary surveillance modality.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>The SELECT model, incorporating demographics, laboratory findings and ultrasound features (cirrhosis and multiple cirrhotic nodules), demonstrated superior performance compared to existing models.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>The SELECT model effectively identifies viral hepatitis patients with \u2265 2.5% annual HCC risk who would benefit from intensive surveillance using alternative imaging modalities, optimizing resource allocation and achieving higher diagnostic yield.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-025-12060-8","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:21:59Z","timestamp":1761387719000},"page":"2929-2942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatocellular carcinoma risk stratification to identify patients suitable for intensive surveillance in viral hepatitis: the SELECT score"],"prefix":"10.1007","volume":"36","author":[{"given":"Yeun-Yoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Min","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Seok","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeongin","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Kyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HeeSoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Ju","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sook-Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9925-9973","authenticated-orcid":false,"given":"Jeong Hee","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"12060_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"12060_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","volume":"130","author":"B-H Zhang","year":"2004","unstructured":"Zhang B-H, Yang B-H, Tang Z-Y (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417\u2013422. https:\/\/doi.org\/10.1007\/s00432-004-0552-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"12060_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jamaoncol.2016.3147","volume":"3","author":"SY Kim","year":"2017","unstructured":"Kim SY, An J, Lim Y-S et al (2017) MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol 3:456\u2013463. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3147","journal-title":"JAMA Oncol"},{"key":"12060_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1159\/000506834","volume":"9","author":"JH Yoon","year":"2020","unstructured":"Yoon JH, Lee JM, Lee DH et al (2020) A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development. Liver Cancer 9:503\u2013517. https:\/\/doi.org\/10.1159\/000506834","journal-title":"Liver Cancer"},{"key":"12060_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2024.03.048","volume":"81","author":"DH Kim","year":"2024","unstructured":"Kim DH, Yoon JH, Choi MH et al (2024) Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC. J Hepatol 81:461\u2013470. https:\/\/doi.org\/10.1016\/j.jhep.2024.03.048","journal-title":"J Hepatol"},{"key":"12060_CR6","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/hep.30330","volume":"69","author":"H-L Kim","year":"2019","unstructured":"Kim H-L, An J, Park J-A et al (2019) Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology 69:1599\u20131613. https:\/\/doi.org\/10.1002\/hep.30330","journal-title":"Hepatology"},{"key":"12060_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.5009\/gnl230089","volume":"18","author":"P Decharatanachart","year":"2024","unstructured":"Decharatanachart P, Pan-Ngum W, Peeraphatdit T et al (2024) Cost-utility analysis of non-contrast abbreviated magnetic resonance imaging for hepatocellular carcinoma surveillance in cirrhosis. Gut Liver 18:135\u2013146. https:\/\/doi.org\/10.5009\/gnl230089","journal-title":"Gut Liver"},{"key":"12060_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","volume":"73","author":"R Fan","year":"2020","unstructured":"Fan R, Papatheodoridis G, Sun J et al (2020) aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol 73:1368\u20131378. https:\/\/doi.org\/10.1016\/j.jhep.2020.07.025","journal-title":"J Hepatol"},{"key":"12060_CR9","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jhep.2017.07.033","volume":"68","author":"SA Sharma","year":"2018","unstructured":"Sharma SA, Kowgier M, Hansen BE et al (2018) Toronto HCC risk index: a validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J Hepatol 68:92\u201399. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.033","journal-title":"J Hepatol"},{"key":"12060_CR10","doi-asserted-by":"publisher","unstructured":"Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA (2014) Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer 120:3485\u20133493. https:\/\/doi.org\/10.1002\/cncr.28832","DOI":"10.1002\/cncr.28832"},{"key":"12060_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1053\/jhep.2003.50093","volume":"37","author":"RF Vel\u00e1zquez","year":"2003","unstructured":"Vel\u00e1zquez RF, Rodr\u00edguez M, Navascu\u00e9s CA et al (2003) Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37:520\u2013527. https:\/\/doi.org\/10.1053\/jhep.2003.50093","journal-title":"Hepatology"},{"key":"12060_CR12","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","volume":"69","author":"JH Kim","year":"2018","unstructured":"Kim JH, Kim YD, Lee M et al (2018) Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol 69:1066\u20131073. https:\/\/doi.org\/10.1016\/j.jhep.2018.07.018","journal-title":"J Hepatol"},{"key":"12060_CR13","unstructured":"Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360\u2013363"},{"key":"12060_CR14","doi-asserted-by":"publisher","first-page":"8314","DOI":"10.3748\/wjg.v22.i37.8314","volume":"22","author":"HW Lee","year":"2016","unstructured":"Lee HW, Ahn SH (2016) Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol 22:8314\u20138321. https:\/\/doi.org\/10.3748\/wjg.v22.i37.8314","journal-title":"World J Gastroenterol"},{"key":"12060_CR15","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222106","volume":"307","author":"MK Park","year":"2023","unstructured":"Park MK, Lee DH, Hur BY et al (2023) Effectiveness of US surveillance of hepatocellular carcinoma in chronic hepatitis B: US LI-RADS visualization score. Radiology 307:e222106. https:\/\/doi.org\/10.1148\/radiol.222106","journal-title":"Radiology"},{"key":"12060_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000073","volume":"7","author":"AG Singal","year":"2023","unstructured":"Singal AG, Ghaziani TT, Mehta N et al (2023) Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun 7:e0073. https:\/\/doi.org\/10.1097\/HC9.0000000000000073","journal-title":"Hepatol Commun"},{"key":"12060_CR17","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.cgh.2024.08.051","volume":"23","author":"E Koo","year":"2024","unstructured":"Koo E, Seif El Dahan K, Daher D et al (2024) Risk of hepatocellular carcinoma in subcentimeter liver nodules identified on surveillance ultrasound: a systematic review. Clin Gastroenterol Hepatol 23:1320\u20131327.e2. https:\/\/doi.org\/10.1016\/j.cgh.2024.08.051","journal-title":"Clin Gastroenterol Hepatol"},{"key":"12060_CR18","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1007\/s12072-013-9462-z","volume":"7","author":"DH Sinn","year":"2013","unstructured":"Sinn DH, Yi J, Choi MS et al (2013) Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. Hepatol Int 7:1010\u20131018. https:\/\/doi.org\/10.1007\/s12072-013-9462-z","journal-title":"Hepatol Int"},{"key":"12060_CR19","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.240169","volume":"313","author":"A Kamaya","year":"2024","unstructured":"Kamaya A, Fetzer DT, Seow JH et al (2024) LI-RADS US surveillance version 2024 for surveillance of hepatocellular carcinoma: an update to the American College of Radiology US LI-RADS. Radiology 313:e240169. https:\/\/doi.org\/10.1148\/radiol.240169","journal-title":"Radiology"},{"key":"12060_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.14309\/ajg.0000000000002915","volume":"120","author":"S-C Huang","year":"2025","unstructured":"Huang S-C, Su T-H, Tseng T-C et al (2025) Pre-existing and new-onset metabolic dysfunctions increase cirrhosis and its complication risks in chronic hepatitis B. Am J Gastroenterol 120:401\u2013409. https:\/\/doi.org\/10.14309\/ajg.0000000000002915","journal-title":"Am J Gastroenterol"},{"key":"12060_CR21","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/hep.32792","volume":"77","author":"X Mao","year":"2023","unstructured":"Mao X, Cheung KS, Peng C et al (2023) Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis. Hepatology 77:1735\u20131745. https:\/\/doi.org\/10.1002\/hep.32792","journal-title":"Hepatology"},{"key":"12060_CR22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s12072-024-10639-9","volume":"18","author":"I Ayada","year":"2024","unstructured":"Ayada I, Li J, Brouwer WP et al (2024) Impact of chronic hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma. Hepatol Int 18:1053\u20131055. https:\/\/doi.org\/10.1007\/s12072-024-10639-9","journal-title":"Hepatol Int"},{"key":"12060_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3350\/cmh.2018.0054","volume":"25","author":"DS Kim","year":"2019","unstructured":"Kim DS, Jeon MY, Lee HW et al (2019) Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. Clin Mol Hepatol 25:283\u2013293. https:\/\/doi.org\/10.3350\/cmh.2018.0054","journal-title":"Clin Mol Hepatol"},{"key":"12060_CR24","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","volume":"17","author":"S-C Huang","year":"2023","unstructured":"Huang S-C, Su T-H, Tseng T-C et al (2023) Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int 17:1139\u20131149. https:\/\/doi.org\/10.1007\/s12072-023-10545-6","journal-title":"Hepatol Int"},{"key":"12060_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/MCG.0000000000001217","volume":"54","author":"H Cho","year":"2020","unstructured":"Cho H, Chang Y, Lee J-H et al (2020) Radiologic nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with suppressed chronic hepatitis B. J Clin Gastroenterol 54:633\u2013641. https:\/\/doi.org\/10.1097\/MCG.0000000000001217","journal-title":"J Clin Gastroenterol"},{"key":"12060_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/apt.16706","volume":"55","author":"MN Kim","year":"2022","unstructured":"Kim MN, Han K, Yoo J et al (2022) Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver. Aliment Pharmacol Ther 55:97\u2013107. https:\/\/doi.org\/10.1111\/apt.16706","journal-title":"Aliment Pharmacol Ther"},{"key":"12060_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3350\/cmh.2018.0040","volume":"25","author":"YB Lee","year":"2019","unstructured":"Lee YB, Ha Y, Chon YE et al (2019) Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol 25:52\u201364. https:\/\/doi.org\/10.3350\/cmh.2018.0040","journal-title":"Clin Mol Hepatol"},{"key":"12060_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","volume":"1","author":"N Peleg","year":"2019","unstructured":"Peleg N, Issachar A, Sneh Arbib O et al (2019) Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep 1:9\u201316. https:\/\/doi.org\/10.1016\/j.jhepr.2019.02.002","journal-title":"JHEP Rep"},{"key":"12060_CR29","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12072-021-10205-7","volume":"15","author":"JH Oh","year":"2021","unstructured":"Oh JH, Lee HW, Sinn DH et al (2021) Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatol Int 15:892\u2013900. https:\/\/doi.org\/10.1007\/s12072-021-10205-7","journal-title":"Hepatol Int"},{"key":"12060_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s12072-021-10218-2","volume":"15","author":"L-Y Mak","year":"2021","unstructured":"Mak L-Y, Hui RW-H, Fung J et al (2021) Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. Hepatol Int 15:901\u2013911. https:\/\/doi.org\/10.1007\/s12072-021-10218-2","journal-title":"Hepatol Int"},{"key":"12060_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jhep.2024.12.009","volume":"83","author":"S-C Huang","year":"2025","unstructured":"Huang S-C, Su T-H, Tseng T-C et al (2025) All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease. J Hepatol 83:43\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.009","journal-title":"J Hepatol"},{"key":"12060_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hep.32341","volume":"76","author":"I Lockart","year":"2022","unstructured":"Lockart I, Yeo MGH, Hajarizadeh B et al (2022) HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis. Hepatology 76:139\u2013154. https:\/\/doi.org\/10.1002\/hep.32341","journal-title":"Hepatology"},{"key":"12060_CR33","doi-asserted-by":"publisher","unstructured":"Pol S, ANRS\/AFEF Study Group (2021) Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF\/ANRS CO22 Hepather cohort. Aliment Pharmacol Ther 53:616\u2013629. https:\/\/doi.org\/10.1111\/apt.16197","DOI":"10.1111\/apt.16197"},{"key":"12060_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2022.110328","volume":"151","author":"JA Hwang","year":"2022","unstructured":"Hwang JA, Kang TW, Min JH et al (2022) Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma. Eur J Radiol 151:110328. https:\/\/doi.org\/10.1016\/j.ejrad.2022.110328","journal-title":"Eur J Radiol"},{"key":"12060_CR35","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1148\/radiol.2020192437","volume":"296","author":"RG Barr","year":"2020","unstructured":"Barr RG, Wilson SR, Rubens D et al (2020) Update to the Society of Radiologists in ultrasound liver elastography consensus statement. Radiology 296:263\u2013274. https:\/\/doi.org\/10.1148\/radiol.2020192437","journal-title":"Radiology"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12060-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-12060-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12060-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:19:47Z","timestamp":1774883987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-12060-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["12060"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-12060-8","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Jeong Hee Yoon, MD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors (Y. Choi, PhD) has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained (IRB No.: H-2108-107-1245 for Seoul National University Hospital; B-2209-782-401 for Seoul National University Bundang Hospital; 4-2022-0698 for Severance Hospital).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Study subjects or cohorts have not been previously reported.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}